| 國立成功大學 |
2024-12 |
Geographic differences in susceptibility profiles of potential non-class B carbapenemase-producing Enterobacterales isolates against ceftazidime-avibactam, meropenem-vaborbactam, colistin, amikacin, gentamicin, and tigecycline: Data from the Antimicrobial
|
Jean;Shio-Shin;Ko;Wen-Chien;Liu;I-Min;Hsieh;Po-Chuen;Hsueh;Po-Ren |
| 國立成功大學 |
2024-07 |
Burkholderia gladioli and bongkrekic acid: An under-recognized foodborne poisoning outbreak
|
Lai;Chih-Cheng;Wang;Jiun-Ling;Hsueh;Po-Ren |
| 國立成功大學 |
2024-05-17 |
Global epidemiology and antimicrobial resistance of Enterobacterales harbouring genes encoding OXA-48-like carbapenemases: insights from the results of the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme 2018-2021
|
Lee;Yu-Lin;Wang;Wei-Yao;Ko;Wen-Chien;Hsueh;Po-Ren |
| 國立成功大學 |
2024-04 |
Global trends in nonsusceptibility rates of Escherichia coli isolates to meropenem and ceftazidime/avibactam: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014-21
|
Wang;Jiun-Ling;Lai;Chih-Cheng;Tsai;Ya-Wen;Hsueh;Chun-Chung;Ko;Wen-Chien;Hsueh;Po-Ren |
| 國立成功大學 |
2024-03 |
Minimum inhibitory concentrations of antifungals against invasive isolates of Cryptococcus species worldwide: Global antifungal antimicrobial testing leadership and surveillance program, 2010-2020
|
Jean;Shio-Shin;Liu;Chia-Ying;Huang;Yu-Tsung;Ko;Wen-Chien;Ho;Mao-Wang;Liu;I-Min;Hsieh;Po-Chuen;Hsueh;Po-Ren |
| 國立成功大學 |
2024-02 |
Global trends in non-susceptibility rates of Streptococcus pneumoniae isolates to ceftriaxone: Data from the antimicrobial testing leadership and surveillance (ATLAS) programme, 2016-21
|
Wang;Jiun-Ling;Lai;Chih-Cheng;Ko;Wen-Chien;Hsueh;Po-Ren |
| 國立成功大學 |
2023-09 |
Geographical patterns of in vitro susceptibilities to tigecycline and colistin among worldwide isolates of Acinetobacter baumannii, Escherichia coli and Klebsiella pneumoniae: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program
|
Wang;Jiun-Ling;Lai;Chih-Cheng;Ko;Wen-Chien;Hsueh;Po-Ren |
| 國立成功大學 |
2022-12 |
Reappraisal of the clinical role of metronidazole therapy for Clostridioides difficile infection in Taiwan: A multicenter prospective study
|
Lee;Jen-Chieh;Lee;Ching-Chi;Chiu;Chun-Wei;Tsai;Pei-Jane;Hsueh;Po-Ren;Lee;Yuan-Ti;Hung;Yuan-Pin;Ko;Wen-Chien |
| 國立成功大學 |
2022-10 |
A brief on new waves of monkeypox and vaccines and antiviral drugs for monkeypox
|
Hung;Yuan-Pin;Lee;Ching-Chi;Lee;Jen-Chieh;Chiu;Chun-Wei;Hsueh;Po-Ren;Ko;Wen-Chien |
| 國立成功大學 |
2022-06 |
Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan
|
Kang;Chun-Min;Lee;Nan-Yao;Lin;Chih-Hsueh;Hsu;Yuan-Shan;Chang;Yu-Chang;Chung;Ming-Yi;Lee;Ya-Fan;Tseng;Wen-Pin;Wu;Jhong-Lin;Chen;Shey-Ying;Lu;Min-Chi;Ko;Wen-Chien;Lee;Ping-Ing;Hsueh;Po-Ren |
| 國立成功大學 |
2021-12-2 |
Clostridioides difficile infection: an emerging zoonosis?
|
Tsai;Chin-Shiang;Hung;Yuan-Pin;Lee;Jen-Chieh;Syue;Ling-Shan;Hsueh;Po-Ren;Ko;Wen-Chien |
| 國立成功大學 |
2021-12 |
Clostridioides difficile infection in patients with hematological malignancy: A multicenter study in Taiwan
|
Hung;Yuan-Pin;Tsai;Chin-Shiang;Tsai;Bo-Yang;Tsai;Pei-Jane;Lee;Yuan-Ti;Lee;Jen-Chieh;Liu;Hsiu-Chuan;Hsueh;Po-Ren;Lee;Ching-Chi;Ko;Wen-Chien |
| 國立成功大學 |
2021-09 |
The Potential of Probiotics to Eradicate Gut Carriage of Pathogenic or Antimicrobial-Resistant Enterobacterales
|
Hung;Yuan-Pin;Lee;Ching-Chi;Lee;Jen-Chieh;Tsai;Pei-Jane;Hsueh;Po-Ren;Ko;Wen-Chien |
| 國立成功大學 |
2020-11-17 |
A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs
|
Chen;Po-Lin;Lee;Nan-Yao;Cia;Cong-Tat;Ko;Wen-Chien;Hsueh;Po-Ren |
| 國立成功大學 |
2020-06 |
A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic
|
Lee;Nan-Yao;Li;Chia-Wen;Tsai;Huey-Pin;Chen;Po-Lin;Syue;Ling-Shan;Li;Ming-Chi;Tsai;Chin-Shiang;Lo;Ching-Lung;Hsueh;Po-Ren;Ko;Wen-Chien |
| 國立成功大學 |
2020-01-1 |
Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan
|
Chen;Shey-Ying;Lee;Yu-Lin;Lin;Yi-Chun;Lee;Nan-Yao;Liao;Chia-Hung;Hung;Yuan-Pin;Lu;Min-Chi;Wu;Jhong-Lin;Tseng;Wen-Pin;Lin;Chien-Hao;Chung;Ming-Yi;Kang;Chun-Min;Lee;Ya-Fan;Lee;Tai-Fen;Cheng;Chien-Yu;Chen;Cheng-Pin;Huang;Chien-Hua;Liu;Chun-Eng;Cheng;Shu-Hsing;Ko;Wen-Chien;Hsueh;Po-Ren;Chen;Shyr-Chyr |
| 國立成功大學 |
2019-10-4 |
Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms
|
Lee;Nan-Yao;Ko;Wen-Chien;Hsueh;Po-Ren |
| 國立成功大學 |
2019 |
Prevalence and risk factors for colonization by extended-spectrum beta-lactamase-producing or ST 131 Escherichia coli among asymptomatic adults in community settings in Southern Taiwan
|
Wu;Pin-Chieh;Wang;Jiun-Ling;Hsueh;Po-Ren;Lin;Po-Hsiang;Cheng;Ming-Fang;Huang;I-Fei;Chen;Yao-Shen;Lee;Susan, Shin-Jung;Guang-Yuan;Mar;Yu;Hsien-Chung;Hsu;Chiao-Lin;Wang;Fu-Wei;Chen;Chi-Shen;Hung;Chih-Hsin;Ko;Wen-Chien |
| 國立成功大學 |
2018-10 |
Implementation of a national bundle care program to reduce central line-associated bloodstream infections in intensive care units in Taiwan
|
Lai;Chih-Cheng;Cia;Cong-Tat;Chiang;Hsiu-Tzy;Kung;Yung-Chung;Shi;Zhi-Yuan;Chuang;Yin-Ching;Lee;Chun-Ming;Ko;Wen-Chien;Hsueh;Po-Ren |
| 國立成功大學 |
2018 |
Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan
|
Hung;Yuan-Pin;Tsai;Pei-Jane;Lee;Yuan-Ti;Tang;Hung-Jen;Lin;Hsiao-Ju;Liu;Hsiu-Chuan;Lee;Jen-Chieh;Tsai;Bo-Yang;Hsueh;Po-Ren;Ko;Wen-Chien |
| 國立成功大學 |
2017-06 |
Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae
|
Lo;Ching-Lung;Lee;Ching-Chi;Li;Chia-Wen;Li;Ming-Chi;Hsueh;Po-Ren;Lee;Nan-Yao;Ko;Wen-Chien |
